Allovir

Closed

Kalaris Therapeutics – Your vision, our mission

Waltham, United States · Founded 2013 · $150.0M raised

Employees
51–200
Founded
2013
Business Model
B2B
Total Funding
$150.0M
Last Round
$120.0M Series BMay 2019
Rounds
2

About

AlloVir (formerly ViraCyte) was a clinical-stage biopharmaceutical company founded in 2013 out of Baylor College of Medicine's Center for Cell and Gene Therapy, headquartered in Waltham, Massachusetts. The company was the leader in developing allogeneic, off-the-shelf, multi-virus-specific T-cell therapies to restore natural immunity in immunocompromised patients against life-threatening viral diseases. AlloVir was an ElevateBio portfolio company and was publicly traded on Nasdaq. In November 2024, AlloVir and Kalaris Therapeutics announced a merger agreement, effectively ending AlloVir's independent operations.

Summary

Allovir is a Biotech company based in Waltham, United States, founded in 2013. It has raised $150.0M in total across 2 rounds, most recently a $120.0M Series B round in May 2019. Investors include Gilead Sciences and F2 Ventures.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOAug 2020
$317.7M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Allovir on Indexed.vc
<a href="https://indexed.vc/companies/allovir"><img src="https://indexed.vc/api/badge/company/allovir" alt="Allovir on Indexed.vc" width="260" height="76" /></a>